Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(5): 282-287
DOI: 10.1055/s-2005-865650
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Leu7Pro Polymorphism in the Neuropeptide Y (NPY) Gene is Associated with Impaired Glucose Tolerance and Type 2 Diabetes in Swedish Men

S. Nordman1 , B. Ding2 , C.-G. Östenson1 , L. Kärvestedt3 , K. Brismar1 , S. Efendic1 , H. F. Gu1
  • 1Diabetes Center Karolinska, Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden
  • 2Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
  • 3Stockholm Hospital, Stockholm, Sweden
Further Information

Publication History

Received: July 5, 2004 First decision: September 20, 2004

Accepted: February 7, 2005

Publication Date:
30 May 2005 (online)

Also available at
    Permissions and Reprints

Abstract

The neuropeptide Y (NPY) is a neuropeptide with a role in the regulation of satiety and energy balance of body weight, insulin release, cardiovascular and central endocrine systems. In order to evaluate whether the NPY gene variations contribute to development of type 2 diabetes (T2DM), we have performed a genetic association study for Leu7Pro (T1128 C) polymorphism of the NPY gene in impaired glucose tolerance (IGT) and T2DM. Genotyping experiments for this non-synonymous single nucleotide polymorphism (SNP) in 263 patients with T2DM, 309 subjects with IGT and 469 non-diabetic healthy individuals in Swedish Caucasians were performed by using Dynamic Allele Specific Hybridisation (DASH). We found that the frequencies of the “risk” allele C in the subjects with IGT and the patients with T2DM in Swedish men were 13 % (p = 0.002, OR = 3.70, 1.65 - 8.29 95 % CI) and 10 % (p = 0.007, OR = 4.80, 1.47 - 11.33 95 % CI) respectively, which were significantly higher than the C allele frequency in non-diabetic controls (6 %). Furthermore, we found that the carriers with TC and CC genotypes in the subjects with IGT in Swedish men had significantly higher fasting plasma glucose in comparison with the TT carriers (5.6 ± 0.7 mmol/l vs. 5.2 ± 0.7 mmol/l, p = 0.021). The present study thus provides the evidence that Leu7Pro polymorphism in the NPY gene is associated with IGT and T2DM in Swedish men, and indicates that the NPY gene variations contribute to development of T2DM. Questions of gender specificity may be explained by genetic backgrounds, sense of coherence for stress and other factors in environment.

Key words

Neuropeptide Y - type 2 diabetes - impaired glucose tolerance - single nucleotide polymorphism - genetic association

References

  • 1 Agardh E E, Ahlbom A, Andersson T, Efendic S, Grill V, Hallqvist J, Norman A, Ostenson C G. Work stress and low sense of coherence is associated with type 2 diabetes in middle-aged Swedish women.  Diabetes Care. 2003;  26 719-724
    PubMedGoogle Scholar
  • 2 Bargsten G. Cytological and immunocytochemical characterization of the insulin secreting insulinoma cell line RINm5 F.  Arch Histol Cytol. 2004;  67 79-94
    PubMedGoogle Scholar
  • 3 Billington C J, Briggs J E, Grace M, Levine A S. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism.  Am J Physiol. 1991;  260 R321-327
    PubMedGoogle Scholar
  • 4 Billington C J, Briggs J E, Harker S, Grace M, Levine A S. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism.  Am J Physiol. 1994;  266 R1765-1770
    PubMedGoogle Scholar
  • 5 Blumenthal J B, Andersen R E, Mitchell B D, Seibert M J, Yang H, Herzog H, Beamer B A, Franckowiak S C, Walston J D. Novel neuropeptide Y1 and Y5 receptor gene variants: associations with serum triglyceride and high-density lipoprotein cholesterol levels.  Clin Genet. 2002;  62 196-202
    CrossrefPubMedGoogle Scholar
  • 6 Cho Y R, Kim C W. Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation.  Biochem Biophys Res Commun. 2004;  314 773-780
    CrossrefPubMedGoogle Scholar
  • 7 Ding B, Bertilsson L, Wahlestedt C. The single nucleotide polymorphism T1128 C in the signal peptide of neuropeptide Y (NPY) was not identified in a Korean population.  J Clin Pharm Ther. 2002;  27 211-212
    CrossrefPubMedGoogle Scholar
  • 8 Ding B. Distribution of the NPY 1128C allele frequency in different populations.  J Neural Transm. 2003;  110 1199-1204
    CrossrefPubMedGoogle Scholar
  • 9 Gu H F, Efendic S, Nordman S, Östensson C G, Brismar K, Brookes A J, Prince J P. Quantitative trait loci near the insulin-degrading enzyme gene (IDE) contribute to variation in plasma insulin levels.  Diabetes. 2004;  53 2137-2142
    PubMedGoogle Scholar
  • 10 Howell M W, Jobs M, Gyllensten U, Brookes A J. Dynamic allele-specific hybridisation: A new method for scoring single nucleotide polymorphisms.  Nature Biotech. 1999;  17 87-88
    CrossrefPubMedGoogle Scholar
  • 11 Kallio J, Pesonen U, Kaipio K, Karvonen M K, Jaakkola U, Heinonen O J, Uusitupa M I, Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans.  FASEB J. 2001;  15 1242-1244
    PubMedGoogle Scholar
  • 12 Karvonen M K, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker J M, Hart L M, Valve R, Uusitupa M I. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels.  Nat Med. 1998;  4 1434-1437
    PubMedGoogle Scholar
  • 13 Karvonen M K, Valkonen V P, Lakka T A, Salonen R, Koulu M, Pesonen U, Tuomainen T P, Kauhanen J, Nyyssonen K, Lakka H M, Uusitupa M I, Salonen J T. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men.  Atherosclerosis. 2001;  159 145-151
    CrossrefPubMedGoogle Scholar
  • 14 Koehnke M D, Schick S, Lutz U, Willecke M, Koehnke A M, Kolb W, Gaertner I. Severity of alcohol withdrawal symptoms and the T1128 C polymorphism of the neuropeptide Y gene.  J Neural Transm. 2002;  109 1423-1429
    CrossrefPubMedGoogle Scholar
  • 15 Kuhl J, Hilding A, Östenson C-G, Grill V, Efendic S, Båvenholm P. Characterization of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Program: The impact of gender and type 2 diabetes heredity.  Diabetologia. 2005;  48 35-40
    CrossrefPubMedGoogle Scholar
  • 16 Levine A S, Jewett D C, Cleary J P, Kotz C M, Billington C J. Our journey with neuropeptide Y: effects on ingestive behaviors and energy expenditure.  Peptides. 2004;  25 505-510
    CrossrefPubMedGoogle Scholar
  • 17 Makino K, Kataoka Y, Hirakawa Y, Ikeda A, Yamauchi A, Oishi A R. A leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y was not identified in the Japanese population.  J Clin Pharm Ther. 2001;  26 201-203
    CrossrefPubMedGoogle Scholar
  • 18 McCarthy J J, Meyer J, Moliterno D J, Newby L K, Rogers W J, Topol E J. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients.  Hum Genet. 2003;  114 87-98
    PubMedGoogle Scholar
  • 19 Minth C D, Andrews P C, Dixon J E. Characterization, sequence, and expression of the cloned human neuropeptide Y gene.  J Biol Chem. 1986;  261 11974-11979
    PubMedGoogle Scholar
  • 20 Moltz J H, McDonald J K. Neuropeptide Y: direct and indirect action on insulin secretion in the rat.  Peptides. 1985;  6 1155-1159
    CrossrefPubMedGoogle Scholar
  • 21 Morris M J, Pavia J M. Increased endogenous noradrenaline and neuropeptide Y release from the hypothalamus of streptozotocin diabetic rats.  Brain Res. 2004;  1006 100-106
    CrossrefPubMedGoogle Scholar
  • 22 Niskanen L, Karvonen M K, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J, Laakso M, Uusitupa M I. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects.  J Clin Endocrinol Metab. 2000 a;  85 2266-2269
    CrossrefPubMedGoogle Scholar
  • 23 Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen M K, Valve R, Pesonen U, Laakso M, Uusitupa M I, Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2000 b;  108 235-236
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Pettersson-Fernholm K, Karvonen M K, Kallio J, Forsblom C M, Koulu M, Pesonen U, Fagerudd J A, Groop P H. FinnDiane Study Group . Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients.  Diabetes Care. 2004;  27 503-509
    PubMedGoogle Scholar
  • 25 Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U, Kallio J, Uusitupa M, Laakso M. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism.  Metabolism. 2003;  52 643-646
    CrossrefPubMedGoogle Scholar
  • 26 Takeuchi T, Gumucio D L, Yamada T, Meisler M H, Minth C D, Dixon J E, Eddy R E, Shows T B. Genes encoding pancreatic polypeptide and neuropeptide Y are on human chromosomes 17 and 7.  J Clin Invest. 1986;  77 1038-1041
    PubMedGoogle Scholar
  • 27 Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.  Nature. 1982;  296 659-660
    CrossrefPubMedGoogle Scholar
  • 28 Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide.  Proc Natl Acad Sci USA. 1982;  79 5485-5489
    CrossrefPubMedGoogle Scholar
  • 29 Waldbieser G C, Minth C D, Chrisman C L, Dixon J E. Tissue-specific expression of the human neuropeptide Y gene in transgenic mice.  Brain Res Mol Brain Res. 1992;  14 87-93
    PubMedGoogle Scholar
  • 30 Zhu G, Pollak L, Mottagui-Tabar S, Wahlestedt C, Taubman J, Virkkunen M, Goldman D, Heilig M. NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations.  Alcohol Clin Exp Res. 2003;  27 19-24
    PubMedGoogle Scholar

Harvest F. Gu

L6:B2, Diabetes Center Karolinska, Department of Molecular Medicine, Karolinska Hospital

Stockholm, 171 76

Sweden

Phone: + 46851779515

Fax: + 46 8 51 77 36 58

Email: harvest.gu@molmed.ki.se